Silicon phthalocyanine (pc 4) photodynamic therapy is a safe modality for cutaneous neoplasms: Results of a phase 1 clinical trial

Lasers in Surgery and Medicine

Volumn 42, Issue 10, 2010, Pages 888-895

  Baron, Elma D ^a,b   Malbasa, Christi L ^a   Santo Domingo, Diana ^a   Fu, Pingfu ^a   Miller, Janine D ^a   Hanneman, Kaija K ^a   Hsia, Andrew H ^a   Oleinick, Nancy L ^a   Colussi, Valdir C ^a   Cooper, Kevin D ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

Author keywords

apoptosis; mycosis fungoides; non melanoma skin cancer; photodynamic therapy; photosensitizer; silicon phthalocyanine

Indexed keywords

CASPASE 3; PHOTOSENSITIZING AGENT; SILICON PHTHALOCYANINE PC 4; UNCLASSIFIED DRUG;

ACTINIC KERATOSIS; ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; BOWEN DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; FAR RED LIGHT; FEMALE; HUMAN; MALE; MYCOSIS FUNGOIDES; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RADIATION ABSORPTION; RADIATION DOSE; RADIATION SAFETY; SKIN CANCER; SQUAMOUS CELL CARCINOMA;

EID: 78751678102     PISSN: 01968092     EISSN: 10969101     Source Type: Journal    
DOI: 10.1002/lsm.20984     Document Type: Article

References (29)

1. Braathen LR, Szeimies RM, Basset-Seguin N, Bissonnette R, Foley P, Pariser D, Roelandts R, Wennberg AM, Morton CA,. Guidelines on the use of photodynamic therapy for nonmelanoma skin caner: An international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. J Am Acad Dermatol 2007; 56: 125-143.
2. Morton C, Campbell S, Gupta G, Keohane S, Lear J, Zaki I, Walton S, Kerrouche N, Thomas G, Soto P, AKtion Investigators. Intraindividual, right-left comparison of topical methyl aminolaevulinate-photodynamic therapy and cryotherapy in subjects with actinic keratoses: A multicentre, randomized controlled study. Br J Dermatol 2006; 1: 66-71.
3. Steinbauer JM, Schremi S, Babilas P, Zeman F, Karrer S, Landthaler M, Szeimies RM,. Topical photodynamic therapy with porphyrin precursors-assessment of treatment-associated pain in a retrospective study. Photochem Photobiol Sci 2009; 8: 1111-1116.
4. Grapengiesser S, Gudmundsson F, Larkö O, Ericson M, Rosén A, Wennberg A-M,. Pain caused by photodynamic therapy of skin cancer. Clin Exp Dermatol 2002; 27: 493-497.
5. He J, Larkin HE, Li Y, Rihter BS, Zaidi S, Rodgers M, Mukhtar H, Kenney ME, Oleinick NL,. The synthesis, photophysical and photobiological properties and in vitro structureâActivity relationships of a set of silicon phthalocyanine PDT photosensitizers. Photochem Photobiol 1997; 65: 581-586.
6. Ahmad N, Gupta S, Feyes DK, Muktar H,. Involvement of fas (APO-1/CD-95) during photodynamic-therapy-mediated apoptosis in human epidermoid carcinoma cells. J Invest Dermatol 2000; 115: 1041-1046.
7. Ke MS, Xue L, Feyes D, Azizuddin K, Baron ED, McCormick TS, Mukhtar H, Panneerselvam A, Schluchter MD, Cooper KD, Oleinick NL, Stevens SR,. Apoptosis mechanisms related to the increased sensitivity of Jurkat T-cells vs A431 epidermoid cells to photodynamic therapy with the phthalocyanine Pc 4. Photochem Photobiol 2008; 84: 407-414.
8. Colussi VC, Feyes DK, Mulvihill JW, Li YS, Kenney ME, Elmets CA, Oleinick NL, Mukhtar H,. Phthalocyanine (Pc 4) photodynamic therapy of human OVCAR-3 tumor xenografts. Photochem Photobiol 1999; 69 (2): 236-241.
9. Oken M, Creech R, Tormey D, Horton J, Davis T, McFadden E, Carbone P,. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clinic Oncol 1982; 5: 649-655.
10. COLIPA Task Force: Sun protection measurement. sun protection factor test method. October 1994.
11. Ferguson J, Brown M, Alert D, Bielfeldt S, Brown J, Chardon A, Hourseau C, Mazilier C, Cuthbert J, D'Arcy-Burt K, Jolley J, Murdoch M, Finkel P, Masson P, Merot F, Maclennan A, Poret J, Siladgi S,. Collaborative development of a sun protection factor test method: A proposed European standard. Int J Cosm Sci 1996; 18: 203-218.
12. Brown LD, Cai TT, DasGupta A,. Interval estimation for a binomial proportion-comment-rejoinder. Stat Sci 2001; 16 (2): 101-133.
13. Weinstock MA, Gardstein B,. Twenty-year trends in the reported incidence of mycosis fungoides and associated mortality. Am J Public Health 1999; 89: 1240-1244.
14. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, Ralfkiaer E, Chimenti S, Diaz-Perez JL, Duncan LM, Grange F, Harris NL, Kempf W, Kerl H, Kurrer M, Knobler R, Pimpinelli N, Sander C, Santucci M, Sterry W, Vermeer MH, Wechsler J, Whittaker S, Meijer CJ,. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768-3785.
15. Zackheim HS, Amin S, Kashani-Sabet M, McMillan A,. Prognosis in cutaneous T-cell lymphoma by skin stage: Long-term survival in 489 patients. J Am Acad Dermatol 1999; 40: 418-425.
16. Breneman D, Duvic M, Kuzel T, Yocum R, Truglia J, Stevens VJ,. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol 2002; 138: 325-332.
17. Vonderheid EC, Tan ET, Kantor AF, Shrager L, Micaily B, Van Scott EJ,. Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T-cell lymphoma. J Am Acad Dermatol 1989; 20: 416-428.
18. Zackheim HS, Epstein EH, Jr., Crain WR,. Topical carmustine (BCNU) for cutaneous T-cell lymphoma: A 15-year experience in 143 patients. J Am Acad Dermatol 1990; 22: 802-810.
19. Querfeld C, Rosen T, Kuzel TM, Kirby KA, Roenigk HH, Jr., Prinz BM, Guitart J,. Long-term follow up of patients with early stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UVA monotherapy. Arch Dermatol 2005; 141: 305-311.
20. Zane C, Venturini M, Sala R, Calzavara-Pinton P,. Photodynamic therapy with methylaminolevulinate as a valuable treatment option for unilesional cutaneous T-cell lymphoma. Photodermatol Photoimmunol Photomed 2006; 22 (5): 254-258.
21. Paech V, Lorenzen T, Stoehr A, Lange K, Merz H, Meigel WN, Plettenberg A,. Remission of a cutaneous Mycosis fungoides after topical 5-ALA sensitization and photodynamic therapy in a patient with advanced HIV-infection. Eur J Med Res 2002; 7 (11): 477-479.
22. Edstrom DW, Porwit A, Ros AM,. Photodynamic therapy with topical 5-aminolevulinic acid for mycosis fungoides: Clinical and histological response. Acta Derm Venereol 2001; 81 (3): 184-188.
23. Orenstein A, Haik J, Tamir J, Winkler E, Trau H, Malik Z, Kostenich G,. Photodynamic therapy of cutaneous lymphoma using 5-aminolevulinic acid topical application. Dermatol Surg 2000; 26 (8): 765-769; discussion 769-770.
24. Ketabchi A, MacRobert A, Speight PM, Bennett JH,. Induction of apoptotic cell death by photodynamic therapy in human keratinocytes. Arch Oral Biol 1998; 43: 143-149.
25. Buytaert E, Dewaele M, Agnostinis P,. Molecular effectors of multiple cell death pathways initiated by photodynamic therapy. Biochem Biophys Acta 2007; 1776: 86-107.
26. Oleinick NL, Morris RL, Belichenko I,. The role of apoptosis in response to photodynamic therapy: What, where, why and how. Photochem Photobiol Sci 2002; 1: 1-21.
27. Whitacre CM, Satoh TH, Xue L, Gordon NH, Oleinick NL,. Photodynamic therapy of human breast cancer xenografts lacking caspase-3. Cancer Lett 2002; 179: 43-49.
28. Xue LY, Chiu SM, Oleinick NL,. Photodynamic therapy-induced death of MCF-7 human breast cancer cells: A role for caspase-3 in the late steps of apoptosis but not for the critical lethal event. Exp Cell Res 2001; 263: 145-155.
29. Zhao B, Yin JJ, Bilski PJ, Chignell CF, Roberts JE, He YY,. Enhanced photodynamic efficacy towards melanoma cells by encapsulation of Pc4 in silica nanoparticles. Toxicol Appl Pharmacol 2009; 241: 163-172.